New York-based Synchron, a brain-computer interface (BCI) company, has released a video showing an ALS patient using an iPad controlled entirely by thought in what it says is the "first-ever public ...

SAVANNAH, GEORGIA — Remote monitoring of respiratory scores in patients with amyotrophic lateral sclerosis (ALS) helps predict the best timing for the introduction of bilevel positive airway pressure ...

The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...

For almost a decade, I’ve fought for a cure for a disease I don’t even have yet. In 2018, when my mom was dying of the fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS), I learned ...

NEW ORLEANS--(BUSINESS WIRE)--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) ...

Unlike other pathologies, amyotrophic lateral sclerosis (ALS) cannot be reproduced accurately in animal models, complicating the development of effective drugs. Faced with this challenge, a group of ...

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease that affects the neurons in the brain and spinal cord. In the United States alone there are ...

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he's unwaveringly honest. "Patients always ask me, 'What can I hope to get ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A simple non-invasive hair-based test could one day help with early ...

Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally NEW ORLEANS, [November 14, 2024] — In a landmark continuing ...